Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EPS (Weighted Average and Diluted) (2022 - 2025)

Historic EPS (Weighted Average and Diluted) for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$0.52.

  • ARS Pharmaceuticals' EPS (Weighted Average and Diluted) fell 16000.0% to -$0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.82, marking a year-over-year decrease of 6078.43%. This contributed to the annual value of $0.08 for FY2024, which is 11370.39% up from last year.
  • ARS Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$0.52 in Q3 2025, which was down 16000.0% from -$0.46 recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' EPS (Weighted Average and Diluted) peaked at $0.46 during Q4 2024, and registered a low of -$0.52 during Q3 2025.
  • Its 4-year average for EPS (Weighted Average and Diluted) is -$0.2, with a median of -$0.2 in 2024.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 75849.93% in 2024, then plummeted by 25384.62% in 2025.
  • Over the past 4 years, ARS Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.39 in 2022, then skyrocketed by 81.89% to -$0.07 in 2023, then soared by 758.5% to $0.46 in 2024, then plummeted by 212.81% to -$0.52 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.52 for Q3 2025, versus -$0.46 for Q2 2025 and -$0.35 for Q1 2025.